Orexo (ORX.ST) Stock Price
Orexo Price
Revenue at Orexo has contracted by 8.2% per year over the past 19 years to 26.00 M SEK. Earnings per share have grown at 94.8% per year over the last 3 years. Orexo's net margin stands at -499.2%, down from -39.6% several years earlier.
Orexo stock price
Orexo business model & stock analysis
Frequently asked questions about Orexo
The business model of Orexo AB revolves around the development and commercialization of innovative pharmaceutical products. Orexo focuses on improving the treatment options for patients suffering from opioid dependence and pain management. The company leverages its expertise in formulation technologies and clinical development to create patented products with unique characteristics. Orexo's flagship product, Zubsolv®, is a leading medication for opioid dependence, providing convenient and effective treatment. Through collaborations and strategic partnerships, Orexo aims to expand its product portfolio and geographical presence, delivering value to patients, healthcare professionals, and stakeholders.
Orexo AB is primarily active in the pharmaceutical industry.
The main competitors of Orexo AB in the market include pharmaceutical companies such as Indivior PLC, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. These companies also operate in the field of addiction medicine and create products and treatments for substance abuse disorders.
Orexo AB is a pharmaceutical company headquartered in Sweden. Founded in 1995, Orexo has a rich history and background in developing innovative treatments for patients with opioid addiction. The company specializes in creating and commercializing unique medications using its proprietary technologies. With a focus on opioid dependence and pain management, Orexo has established itself as a leading player in the pharmaceutical industry. Orexo AB constantly strives to improve patient outcomes and contribute to the overall well-being of individuals dealing with addiction and pain-related issues.
Orexo AB has achieved several significant milestones since its establishment. The company successfully developed and commercialized Zubsolv®, a sublingual treatment for opioid dependence. Orexo AB also received approval for Abstral®, an innovative sublingual rapid-disintegrating tablet for cancer breakthrough pain management. Additionally, the company has secured partnerships and collaborations with multiple pharmaceutical companies, expanding its global reach and product portfolio. Orexo AB's dedication to research and development has led to the successful launch of pharmaceutical products that address unmet medical needs, reinforcing its position as a leading player in the pharmaceutical industry.
Orexo AB is primarily present in several countries and regions worldwide. The company has a significant presence in Europe, including countries like Sweden, Norway, Denmark, and Finland. Additionally, Orexo AB is expanding its footprint in the United States, where it is steadily growing its market presence. With its innovative pharmaceutical solutions and commitment to improving patient outcomes, Orexo AB is dedicated to reaching more regions and markets in the future.
Orexo AB represents values of innovation, integrity, and patient-centricity. As a pharmaceutical company, Orexo is dedicated to developing innovative solutions for the treatment of substance abuse and mental health disorders. The company's corporate philosophy revolves around improving the lives of patients by providing safe and effective medications. Orexo prioritizes ethical conduct, ensuring transparency and adhering to strict regulatory standards. Through its research and development efforts, Orexo aims to address unmet medical needs and make a positive impact on society. With its strong values and commitment to patient well-being, Orexo AB continues to be a trusted name in the pharmaceutical industry.
5 analysts currently rate the Orexo stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Orexo to generate revenue of 19.00 M SEK and earnings per share of -9.76 SEK.
Converted at the current exchange rate, the Orexo share trades at 0.64 EUR (7.11 SEK).
The Orexo share (ORX.ST) is listed on 5 stock exchanges, including: London (0H19.L), Frankfurt (C5G.F), Stockholm (ORX.ST).
Orexo AB is a pharmaceutical company focused on developing innovative medications for the treatment of opioid dependence, pain management, and other diseases. The company was founded in 1995 and is headquartered in Uppsala, Sweden. Orexo AB's business model is based on various divisions that allow the company to market its products at different levels. These divisions include medications for the treatment of opioid dependence, medications for pain management, benefit assessment and market access services, and research and development efforts. The company aims to provide tailored medications and services to meet the needs of patients and healthcare professionals. With its focus on opioid dependence and pain management, Orexo AB is well-positioned to serve a growing demographic and maintain high standards of product safety and quality. The company has a strong history of growth and continues to invest in research and development, making it a significant player in the market for opioid dependence and pain management.
The expected revenue of Orexo is 19.00 M SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Orexo is -338.64 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Orexo is currently -0.73. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Orexo stock.
The price-to-sales ratio (P/S) of Orexo is currently 12.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Orexo stock.
The Eulerpool Quality Score for Orexo is 1/10.
The ISIN of Orexo is SE0000736415. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Orexo is A0HG6G. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Orexo is ORX.ST. The ticker symbol is used to trade Orexo shares on the stock exchange.
Orexo stock
Orexo Peer Group
Orexo Ticker
Orexo FIGI
All fundamentals and in-depth analysis of Orexo
Our stock analysis for Orexo stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orexo. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.